Results 1 to 10 of about 1,115 (163)

Successful Management of Relapsed Severe Immune Thrombocytopenia Using Avatrombopag: A Case Report [PDF]

Case Reports in Hematology
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by increased platelet destruction and impaired platelet production. While thrombopoietin receptor agonists (TPO-RAs), including romiplostim and eltrombopag, have significantly
Sultan Almutairi, Ashraf Warsi, Ahmed Hejazi, Elaf Melibari, Raghad Jar, Amal Almutairi, Asmaa Abughasham, Nuha Firaque   +7 more
doaj   +3 more sources

Data Mining and Safety Analysis of Avatrombopag: A Retrospective Pharmacovigilance Study Based on the US Food and Drug Administration’s Adverse Event Reporting System

Scientific Reports
With its increasing use in the treatment of thrombocytopenia, avatrombopag’s associated adverse events (AEs) pose a major challenge to its clinical application. This study aims to comprehensively study AEs associated with avatrombopag by using real-world
Hong Zhu, Meng Wu
exaly   +3 more sources

Avatrombopag switching from other thrombopoietic agents in severe and persistent cancer treatment-induced thrombocytopenia: a multicentre real-world study [PDF]

Frontiers in Medicine
BackgroundSevere and persistent cancer treatment-induced thrombocytopenia (CTIT) remains a major obstacle to continuation of antineoplastic therapy and faces an increased risk of bleeding.
Ye Zhang, Yanan Liu, Junjie Xu, Qingyang Zhang, Xiaojing Zhu, Jingwei Peng, Gege Feng, Gege Feng, Gege Feng, Jun Peng, Jun Peng, Jun Peng, Jun Peng, Ming Hou, Linlin Shao, Linlin Shao, Linlin Shao, Yan Shi   +17 more
doaj   +3 more sources

Acute myocardial infarction induced by avatrombopag: a case report [PDF]

Frontiers in Pharmacology
BackgroundAvatrombopag, a thrombopoietin receptor agonist (TPO-RA), is used for immune thrombocytopenia (ITP) but confers thrombotic risks. Acute myocardial infarction (AMI) as an adverse event is underreported.SummaryA 58-year-old female with steroid ...
Gou Junqi, Liu Chaohui, Lang Mingjian, Yao Fengyou   +3 more
doaj   +4 more sources

Avatrombopag for the Treatment of Immune Thrombocytopenia

European Journal of Haematology
ABSTRACT Avatrombopag, a second‐generation thrombopoietin receptor agonist (TPO‐RA), represents a significant advancement in the treatment of chronic immune thrombocytopenic purpura (cITP) and a potential therapeutic option for other thrombocytopenic disorders.
Fortunato Morabito, Ernesto Vigna, Antonella Bruzzese   +2 more
exaly   +4 more sources

A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avatrombopag

Scientific Reports
Avatrombopag is a next-generation thrombopoietin receptor agonist approved for the treatment of thrombocytopenia in patients with chronic liver disease scheduled to undergo surgery and thrombocytopenia in patients with chronic immune thrombocytopenia ...
Maohua Chen, Mingzuo Wang
exaly   +2 more sources

Avatrombopag in thrombopoietin receptor agonist-naïve patients with immune thrombocytopenia: real-world treatment patterns and clinical outcomes from the REAL-AVA 3.0 study [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Avatrombopag (AVA) is a thrombopoietin receptor agonist (TPO-RA) approved for patients with immune thrombocytopenia (ITP), but real-world data is limited in TPO-RA-naïve patients. Objectives: To describe treatment patterns and outcomes in TPO-
Sandhya Panch, Abiola Oladapo, Scott Kolodny, Michael Vredenburg, Sarah Lucht, Emily Bland, Prathamesh Pathak, Bruce Feinberg, Debbie Jiang   +8 more
doaj   +2 more sources

Efficacy and safety of avatrombopag in aplastic anemia: a comprehensive review of clinical evidence [PDF]

Therapeutic Advances in Hematology
Aplastic anemia is a bone marrow failure disorder marked by cytopenias that impair oxygen delivery, immune defense, and hemostasis. Standard therapy traditionally combines immunosuppression with or without hematopoietic stem cell transplantation, and ...
Mostafa F. Mohammed Saleh, Abdulrahman Nasiri, Ahmed Kotb Abdrabou, Alfadil Haroon, Hadeel Samarkandi, Hazza Alzahrani, Mahmoud Aljurf, Ali Alahmari   +7 more
doaj   +2 more sources

Avatrombopag for the Treatment of Immune Thrombocytopenia and Thrombocytopenia of Chronic Liver Disease

Journal of Blood Medicine, 2019
Abraham Z Cheloff, Hanny Al-Samkari Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USACorrespondence: Hanny Al-SamkariDivision of Hematology, Massachusetts General Hospital, Suite 118, Room 112, Zero Emerson ...
Hanny Al-Samkari, Abraham Z Cheloff
exaly   +2 more sources

The efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trials [PDF]

Frontiers in Pharmacology
ObjectiveThe objective of this study was to compare and rank the efficacy and safety of different thrombopoietin receptor agonists (TPO-RAs) in the treatment of chemotherapy-induced thrombocytopenia (CIT) among patients with solid tumors.MethodsPubMed ...
Yingyu Lai, Qianni Pan, Shiyu Wang, Qingmao Luo, Zhencong Huang, Mingzhong Wei, Zhouqian Jiang, Wenyan Yi   +7 more
doaj   +2 more sources